Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cotinga Pharmaceuticals Inc COTQF

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.


GREY:COTQF - Post by User

Comment by Sharecropper1on Sep 11, 2017 11:11am
122 Views
Post# 26679617

RE:Gamechanger

RE:GamechangerYes...my reliable sources were at the meting. The only difference between your comments and my sources is that they don't believe that the results of phase one will move the market in any significant way. Not a game changer in their opinion. The balance of your comments are generally agreed. Best of luck in your "big way" participation. I'm on your side.
<< Previous
Bullboard Posts
Next >>